Explore the vast range of titles available.

Healthcare regulatory agencies have mandated a reduction in 30-day hospital readmission rates and have targeted COPD as a major contributor to 30-day readmissions. We aimed to develop and validate a simple tool deploying an artificial neural network (ANN) for early identification of COPD patients with high readmission risk. Using COPD patient data from eight hospitals within a large urban hospital system, four variables were identified, weighted and validated. These included the number of in-patient admissions in the previous 6 months, the number of medications administered on the first day, insurance status, and the Rothman Index on hospital day one. An ANN model was trained to provide a predictive algorithm and validated on an additional dataset from a separate time period. The model was implemented in a smartphone app (Re-Admit) incorporating four input risk factors, and a clinical care plan focused on high-risk readmission candidates was then implemented. Subsequent readmission data was analyzed to assess impact. The areas under the curve of receiver operating characteristics predicting readmission with ANN is 0.77, with sensitivity 0.75 and specificity 0.67 on the separate validation data. Readmission rates in the COPD high-risk subgroup after app and clinical intervention implementation saw a significant 48% decline. Our studies show the efficacy of ANN model on predicting readmission risks for COPD patients. The AI enabled Re-Admit smartphone app predicts readmission risk on day one of the patient’s admission, allowing for early implementation of medical, hospital, and community resources to optimize and improve clinical care pathways.

MDM2 and MDMX are key regulators of the tumor suppressor p53 and are implicated in immune escape mechanisms in lung adenocarcinoma. Overexpression of these proteins inhibits p53 activity, limiting the immune system's ability to recognize and clear tumor cells, contributing to resistance against immune checkpoint inhibitors (ICIs). This study introduces a novel bionic peptide nanodrug, E@MDP, designed to target both MDM2 and MDMX, reactivate p53, and enhance the effectiveness of PD-1 immune checkpoint therapy in lung cancer. E@MDP is constructed using a gold-mediated self-assembly method to form peptide-loaded nanoparticles, which are then encapsulated in erythrocyte membranes, enhancing stability and cell penetration. The physicochemical properties of the bionic nanodrug were evaluated, and its therapeutic efficacy was validated in vitro in LLC cells and in vivo using a syngeneic subcutaneous lung adenocarcinoma mice model. In vitro, E@MDP reinstated functional p53 activity, demonstrating a 2.46-fold upregulation compared to control groups, and significantly promoted tumor cell apoptosis, exhibiting a 3.9-fold enhancement. In vivo, E@MDP potentiated PD-1 checkpoint blockade by reprogramming the tumor immune microenvironment, ultimately driving a nearly two-fold enhancement in tumor regression versus monotherapies. Importantly, the E@MDP nanodrug exhibited favorable safety profiles, with no significant toxicity observed in preclinical models. The E@MDP is a promising strategy for lung cancer immunotherapy and overcomes several limitations of conventional peptide drugs. The bionic nanodrug platform holds great potential for broader applications in cancers characterized by immune evasion.

Background Vaccination against COVID-19 continues apace, but side-effects, both common and severe, continue to be reported. We report here the first published case of COVID-19 vaccine-related encephalitis. Case presentation A young woman presented with acute neuropsychiatric symptoms following recent ChAdOx1 nCoV-19 vaccination. Extensive investigation did not identify alternative causes. Conclusions This difficult case is here described, including presentation, investigation, and management. Further study on neuropsychiatric side-effects of COVID-19 vaccination, including investigation as to whether there may be a causal link, is required.

For centuries, the essence of aesthetic experience has remained one of the most intriguing mysteries for philosophers, artists, art historians and scientists alike. Recently, views emphasizing the link between aesthetics, perception and brain function have become increasingly prevalent (Ramachandran and Hirstein, 1999; Zeki, 1999; Livingstone, 2002; Ishizu and Zeki, 2013). The link between art and the fractal-like structure of natural images has also been highlighted (Spehar et al., 2003; Graham and Field, 2007; Graham and Redies, 2010). Motivated by these claims and our previous findings that humans display a consistent preference across various images with fractal-like statistics, here we explore the possibility that observers' preference for visual patterns might be related to their sensitivity for such patterns. We measure sensitivity to simple visual patterns (sine-wave gratings varying in spatial frequency and random textures with varying scaling exponent) and find that they are highly correlated with visual preferences exhibited by the same observers. Although we do not attempt to offer a comprehensive neural model of aesthetic experience, we demonstrate a strong relationship between visual sensitivity and preference for simple visual patterns. Broadly speaking, our results support assertions that there is a close relationship between aesthetic experience and the sensory coding of natural stimuli.

Aims: Artificial Intelligence Ambient Voice Technology (AI AVT) which uses a large language model to summarise clinical dialogue into electronic notes and GP letters has emerged. Although effective in general practice and medical settings, its potential in psychiatry is unknown. In this proof of concept study, we sought to apply AI AVT into clinical practice for a limited duration. The specific aims were to: Assess the functionality and suitability of AI AVT in a child and adolescent mental health service (CAMHS) outpatient clinic for the selected use cases. Identify whether AI AVT reduces documentation burden during and after clinical consultations, and improves clinician work satisfaction. Identify whether AI AVT is acceptable to patients. Identify potential challenges and issues from a clinician, organisational and patient perspective and to make recommendations for refinements. Methods: We conducted a mixed-methods pre-post (manual versus AVT-assisted documentation) service development pilot with 10 clinician participants in a CAMHS outpatient clinic. Use cases were attention deficit hyperactivity disorder medication reviews, general medical reviews and developmental history assessments. The primary outcome was time taken to complete administrative tasks per patient. Secondary outcomes included qualitative clinician experience and patient/carer perception and acceptability of AVT. Measures including questionnaires, time sheets and focus groups were conducted at baseline and intervention. Data analysis included descriptive statistics and mixed linear regression. Focus groups were audio-recorded before being transcribed and thematically analysed. Results: AVT was used in 351 clinical encounters. Administration time for 251 encounters was recorded (AVT n=171). The median time per encounter reduced from 27 minutes (manual) to 10 minutes (AVT) (p<0.001). On average, AVT-assisted documentation took 45% of the time of manual documentation (p<0.001). Clinician-rated accuracy, quality and efficiency of AVT-assisted documentation was statistically significant in its favour. Patient acceptance was high: only 3 preferred for AVT not to be used (0.85%). 97% felt clinicians were not distracted by taking notes. Thematic analysis from focus groups identified positive effects from AVT (improved productivity and mental wellbeing) balanced by barriers (technological limitations). Conclusion: Although subject to the limitations of a small pilot study, we demonstrated that AVT can be implemented successfully, resulting in significantly reduced documentation burden. To evaluate its scalability and potential to further streamline processes, we are currently in phase 2 which involves expanding the clinical roles of our participants and the use cases across Central & North West London NHS Foundation Trust (5 boroughs).

Aims: Efficient medical record systems are vital for improving workflow, ensuring data accuracy, and maintaining staff satisfaction. At Eastlake and Ferneley psychiatric wards, the medical record system, ‘SystmOne’ proved to be inefficient and fragmented, with essential functions scattered across interfaces. This led to excessive administrative burden, detracted from patient care, and frustrated staff. A pre-implementation survey revealed issues such as excessive time spent on documentation and difficulties locating multidisciplinary input, underscoring the need for systemic change. The aim of this project was to reduce administrative time and improve user satisfaction by 30% by December 2024 through a consolidated visualisation tool. Methods: A before and after study was carried out and Plan-Do-Study-Act (PDSA) cycle methodology was used. A new consolidated visualisation tool was designed to streamline key workflows, including admissions, ward activities, and discharges. Healthcare professionals (doctors and nurses) working across two psychiatric wards were participants on this study. Baseline data was collected including quantitative data on time taken to do daily tasks, and number of clicks; as well as qualitative data in the form of user satisfaction surveys. Training sessions were carried out to enable the staff to proficiently use the visualisation, followed by a roll-out of the visualisation on SystmOne. Post-implementation metrics were collected, including the number of clicks, time per task, and user feedback from follow-up surveys to evaluate the intervention’s impact. Results: The intervention resulted in a 92% reduction in clicks and a 62% reduction in time taken to do daily tasks for doctors, and an 89% reduction in clicks and 87% reduction in time for nurses. Pre-implementation, most tasks took 35–40 minutes, whereas post-implementation tasks were completed in under 5 minutes. Annually, this equated to saving 304 hours for doctors and 440 hours for nurses. Qualitative feedback emphasized ease of use, reduced errors through a traffic-light system, and improved data accessibility. Staff reported increased job satisfaction and less frustration, allowing more time for patient care. Conclusion: The system redesign significantly enhanced workflow efficiency, data quality, and user satisfaction, with clear implications for improved patient safety and care within psychiatric inpatient wards. These findings highlight the value of streamlining documentation systems to reduce administrative burden, enhance staff well-being, and foster patient-centred care. Wider rollout of the tool is recommended, alongside iterative refinements and ongoing evaluations to ensure sustainability and adaptability to evolving clinical needs.

Background/Objectives: Antipsychotic treatment response varies considerably between individuals, with one potential reason being genetic variation affecting the cytochrome P450 enzymes that metabolise them. Methods: With a diverse sample of 453 participants, we studied the influence of CYP1A2, CYP2D6, and CYP3A4 variation on three antipsychotic treatment outcomes: participant-reported adverse antipsychotic drug reactions, health-related quality of life, and the dose of antipsychotic medication prescribed. These measures were taken from the baseline assessment, before a pharmacogenetic intervention was delivered. Results: Over half of our sample (62.9%) were carriers of an allele associated with altered metabolism of antipsychotic medications on CYP2D6 or CYP3A4, the two genes with pharmacogenetic guidelines for antipsychotic medications. Ultrarapid CYP2D6 metabolisers reported significantly lower levels of adverse antipsychotic drug reactions than normal CYP2D6 metabolisers (mean difference: −11.1; 95% confidence interval [CI]: −18.9, −3.3; p = 0.00575). There was also suggestive evidence of lower quality of life scores in those carrying one (mean difference: −0.0863; 95% CI: −0.1806, 0.0081; p = 0.0731) or two copies (mean difference: −0.0803; 95% CI: −0.1734, 0.0129; p = 0.0914) of the CYP1A2*30-inducible allele. Conclusions: Our findings suggest that even when looking at a small number of cytochrome P450 genes, carrying an allele associated with altered antipsychotic medication metabolism is relatively common. We also found evidence that the CYP genotype can influence antipsychotic treatment outcomes, specifically adverse drug reactions and quality of life scores.

Single cell lineage tracing, essential for unraveling cellular dynamics in disease evolution is critical for developing targeted therapies. CRISPR-Cas9, known for inducing permanent and cumulative mutations, is a cornerstone in lineage tracing. The novel homing guide RNA (hgRNA) technology enhances this by enabling dynamic retargeting and facilitating ongoing genetic modifications. Charting these mutations, especially through successive hgRNA edits, poses a significant challenge. Our solution, LINEMAP, is a computational framework designed to trace and map these mutations with precision. LINEMAP meticulously discerns mutation alleles at single-cell resolution and maps their complex interrelationships through a mutation evolution network. By utilizing a Markov Process model, we can predict mutation transition probabilities, revealing potential mutational routes and pathways. Our reconstruction algorithm, anchored in the Markov model's attributes, reconstructs cellular lineage pathways, shedding light on the cell's evolutionary journey to the minutiae of single-cell division. Our findings reveal an intricate network of mutation evolution paired with a predictive Markov model, advancing our capability to reconstruct single-cell lineage via hgRNA. This has substantial implications for advancing our understanding of biological mechanisms and propelling medical research forward.

In reaching its decision to bar Home Depot from Kitsilano, Vancouver city council achieved new lows in ad hoc planning (\"Home Depot vote a city first,\" July 11). Harkening back to the days when zoning for \"no laundromats unless in brick buildings\" was enacted to stave off Chinese laundromats in wooden buildings, council at a whim exercised its bias against category-killer big box retailers.

Prosecutors from the U.S. Department of Justice made two trips to Beijing last month to alert Chinese officials about alleged criminal activities being committed by Ms. [Ma Xiaohong] and Hongxiang Industrial, according to U.S. officials. They specifically cited alleged evidence that the Chinese businesswoman and her companies had aided North Korea's nuclear program and Pyongyang's efforts to evade United Nations and Western sanctions. Ms. Ma couldn't be reached. A Hongxiang Industrial official declined to comment on the Chinese investigation and didn't respond to queries on the U.S. probe. Other company executives declined to comment and declined to relay queries to Ms. Ma. Ms. Ma was a shopping-mall worker and manager at an import-export firm in Dandong, on the North Korea border, before founding Hongxiang Industrial in 2000. She grew her business into a conglomerate, Liaoning Hongxiang Industrial Group, with interests in cross-border trade, hotels and tourism.